Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tipranavir.

Drugs - 1 Jan 2003

Plosker Greg L, Figgitt David P

Abstract excerpt

Tipranavir is a potent and selective non-peptidic HIV-1 protease inhibitor with a markedly improved resistance profile compared with traditional, peptidomimetic protease inhibitors. The presence of five or fewer protease gene mutations or one or two protease inhibitor resistance-associated mutations (PRAMs) is associated with reduced susceptibility to currently available protease inhibitors. However, 16-20...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Administration Schedule
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Pyridines

Share to Pyrones

Share to Sulfonamides

Source

Identifiers

PMID: 12887268
DOI: 10.2165/00003495-200363150-00009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tipranavir.PMID 12887268Read ↗

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Tipranavir: a ritonavir-boosted protease inhibitor.Semantic proximity Read ↗

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.Semantic proximity Read ↗

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Semantic proximity Read ↗

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.Semantic proximity Read ↗

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Semantic proximity Read ↗

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.Semantic proximity Read ↗

Tipranavir.Semantic proximity Read ↗

Successful virological outcome in an HIV-infected individual with a three-class resistant variant and an insertion in the protease genome with a Tipranavir based regimen.Semantic proximity Read ↗

Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation.Semantic proximity Read ↗

Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.Semantic proximity Read ↗

Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.